Paper Details

  1. Home
  2. Paper Details

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.

Author: BartelsH, BartlR, BraunH J, ColdeweyR, DeicherH, FettW, FischerJ T, GöbelB, LeoR, PeestD

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

In a study of 406 people with multiple myeloma, asymptomatic early-stage patients (stages I and II) were followed without treatment until disease progression. Those with symptomatic early-stage disease or stage III disease received various treatments, including melphalan and prednisone (MP), or a combination of chemotherapy drugs (VBAMDex). Response rates to treatment were higher in the VBAMDex group compared to the MP group (64% vs 43%). However, survival was similar in both groups (36 months). After achieving remission, patients were randomly assigned to receive either interferon-alpha or no maintenance treatment. The relapse rate was similar in both groups (50% after 13 months) and interferon-alpha did not improve survival.
Paper Details　
Original Abstract of the Article :
406 untreated multiple myeloma patients of stage I (n = 54), II (n = 148) and III (n = 204) were enrolled in the trial. 51/54 stage I and 60/148 stage II patients were asymptomatic and followed without treatment until disease progression (progression free survival: 60% after 4 years for stage I vers...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0959-8049(94)00452-b

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: Evaluating Treatment Options for Remission and Maintenance

Multiple myeloma is a type of blood cancer. Finding effective treatments for remission induction and maintenance is a major challenge. This prospective trial investigated the effectiveness of different treatment approaches for multiple myeloma.

The study enrolled 406 patients with multiple myeloma. They compared the effectiveness of polychemotherapy, melphalan/prednisone (MP), and interferon-alpha (IFN-alpha) for remission induction and maintenance. The study found that MP was effective for remission induction in stage II patients, while VBAMDex (vincristine/BCNU/doxorubicin/melphalan/dexamethasone) was more effective for stage III patients. IFN-alpha did not show a survival benefit in the maintenance phase.

Multiple Myeloma: Understanding Treatment Options

The study provides valuable insights into the effectiveness of different treatment strategies for multiple myeloma. It highlights the need for individualized treatment plans based on the stage of the disease and patient characteristics.

Navigating the Desert of Multiple Myeloma

Navigating the desert of multiple myeloma requires a well-informed approach. This study helps to illuminate the landscape of treatment options, providing valuable information for patients and their healthcare providers. It emphasizes the importance of personalized care in managing this complex cancer.

Dr.Camel's Conclusion

This study is like a map guiding us through the challenging landscape of multiple myeloma treatment. By understanding the various treatment options and their effectiveness, we can navigate the desert of this disease and create a path towards improved outcomes for patients.

Date :
  1. Date Completed 1995-05-24
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

7718318

DOI: Digital Object Identifier

10.1016/0959-8049(94)00452-b

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.